Page last updated: 2024-11-02

pargyline and Prostatic Neoplasms, Castration-Resistant

pargyline has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies

Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.

Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.

Research Excerpts

ExcerptRelevanceReference
"Pargyline was given intraperitoneally or not after castration (implemented with Bilateral orchidectomy), then PSA levels in serum and tumor were determined to assess time to androgen-independent progression."1.42Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. ( Guo, J; He, L; Jiang, G; Liu, X; Wang, M; Wang, Z; Weng, X, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, M1
Liu, X1
Guo, J1
Weng, X1
Jiang, G1
Wang, Z1
He, L1

Other Studies

1 other study available for pargyline and Prostatic Neoplasms, Castration-Resistant

ArticleYear
Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Biochemical and biophysical research communications, 2015, Nov-13, Volume: 467, Issue:2

    Topics: Animals; Antihypertensive Agents; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement;

2015